 By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update ESSA Pharma Inc. EPIX is a biopharmaceutical company developing treatments for prostate cancer that is no longer responding to current therapies. The company is developing a series of compounds anitens that disrupt the androgen receptor AR signaling pathway through a unique mechanism of action that targets 